During the past decade, Munich Oncologic Practice at Elisenhof conducted 0 clinical trials. In the 10-year time frame, 0 clinical trials started and 2 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Munich Oncologic Practice at Elisenhof" #1 sponsor was "German CLL Study Group" with 5 trials, followed by "German High-Grade Non-Hodgkin's Lymphoma Study Group" with 2 trials sponsored, "Hoffmann-La Roche" with 2 trials sponsored, "European Organisation for Research and Treatment of Cancer - EORTC" with 1 trials sponsored and "Medice Arzneimittel Pütter GmbH & Co KG" with 1 trials sponsored. Other sponsors include -4 different institutions and companies that sponsored additional 6 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Munich Oncologic Practice at Elisenhof" #1 collaborator was "Federation Francophone de Cancerologie Digestive" with 1 trials as a collaborator. Other collaborators include -1 different institutions and companies that were collaborators in the rest 1 trials.

According to Clinical.Site data, the most researched conditions in "Munich Oncologic Practice at Elisenhof" are "Chronic Lymphocytic Leukemia" (5 trials), "Lymphoma" (2 trials), "Anemia" (1 trials), "Breast Cancer" (1 trials) and "Cancer-related Fatigue" (1 trials). Many other conditions were trialed in "Munich Oncologic Practice at Elisenhof" in a lesser frequency.

Most popular intervention types in "Munich Oncologic Practice at Elisenhof" are "Drug" (12 trials), "Biological" (4 trials), "Radiation" (3 trials), "Other" (1 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "Fludarabine" (5 trials), "Cyclophosphamide" (3 trials), "radiation therapy" (3 trials), "cyclophosphamide" (2 trials) and "doxorubicin hydrochloride" (2 trials). Other intervention names were less common.

The vast majority of trials in "Munich Oncologic Practice at Elisenhof" are 11 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Munich Oncologic Practice at Elisenhof". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 11 completed trials in Munich Oncologic Practice at Elisenhof, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Munich Oncologic Practice at Elisenhof, 1 "Phase 1" clinical trials were conducted, 3 "Phase 2" clinical trials and 10 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".